Autism Spectrum Disorder industry

Published: 2019-12-09 08:00:00
463 words
2 pages
4 min to read
Type of paper: 
This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.

Autism Spectrum disorder (ASD) is a group of individuals in the society who are affected by multifaceted neurodevelopment disabilities. Social, behavioral and communication challenges are the main characteristics of those individuals who are affected by ASD. The condition is referred to spectrum condition because all the persons affected by autism in one way or another would share the same difficulties. At some level these individuals their medical conditions will affected them in varied ways. The industry is not well researched therefore there are no medications that can confirm full treatment of ASD. The industry is underserved with only two drugs receiving approval of FDA. Abilify (aripiprazole) and risperidone are the only drugs that are approved.

Global autism spectrum disorder market size

The research indicate that the market size of those affected by autism is highest in the developed countries as compared with developing and third world countries. The market size is based on autistic children per 10,000 children under the study. The top ten countries ranked as per market size are: Portugal(17), Hong Kong(17), Brazil(27), Australia(45), Canada(65), USA(66), Denmark(68), Sweden(72), United Kingdom(94), Japan(161). Japan is the leading country with cases of autism.

Global leading players

Bristol-Myers Squibb and Otsuka Holdings Co, Ltd are the key producers of Abilify. There are many key market players who produce risperidone since it falls under generic market. These key players are Janssen Pharmaceuticals, Inc., Teva Pharmaceutical industries Ltd, Actavis Inc., Mylan Pharmaceuticals, Inc. Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Limited. Asia, Europe and North America has an average prevalence of 1%.

Market Analysis

The market for ASD treatment is open since there are no known medications. The patent for Abilify will expire prompting for new introductions of experts who will improve the current therapeutic medications of ASD. There are six major countries that treat autism. These countries are the US, France, Germany, Italy, Spain, and the UK. According to global autism spectrum disorder consumption 2016 market research it is predicted that there are likelihood of decline in the annual growth rate. The rate are predicted to drop from $1.44 billion in 2013 to $1.4 billion by 2018. Gulf current ASD sales value is 1:68 as compared with global total sales. The Gulf ASD treatment market sales is estimated to reduce from 0.6392 billion in 2012 to 0.6211 billion in 2018. An analysis of European countries indicate a different aspect since it predicted that there will be growth in revenue from ASD treatment. The growth will be $28.9 million in 2013 to $34. 6 million in 2018.

Future of ASD treatment

The fact that there are only two approved drugs used in treating ASD is an indication that the treatment market of ASD is untapped. The current products are only associated with treating irritability associated with ASD. Development of new medical system for autism therapy that will treat weight-neutral and sensitive patients is the future of the industry.


Request Removal

If you are the original author of this essay and no longer wish to have it published on the SpeedyPaper website, please click below to request its removal: